Pancreatic Cancer Research

ResearcherSoutheast UniversityActive in the last 2 years

Shenghong Ju

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5041-7865; OpenAlex author ID A5004012046. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 5 papers · 2026: 1 paper

Papers 13

  1. Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma Last author DOI 10.1038/s41467-026-77665-z↗
  2. Multiparametric MRI for Assessment of the Biological Invasiveness and Prognosis of Pancreatic Ductal Adenocarcinoma in the Era of Artificial Intelligence. Last author DOI 10.1002/jmri.29708↗
  3. Enhancing the tissue penetration to improve sonodynamic immunotherapy for pancreatic ductal adenocarcinoma using membrane-camouflaged nanoplatform. Last author DOI 10.1007/s00259-024-06952-y↗
  4. Targeted intervention in nerve-cancer crosstalk enhances pancreatic cancer chemotherapy. Co-author DOI 10.1038/s41565-024-01803-1↗
  5. Engineering a spatiotemporal macrophage circuit via STING phase separation to override immune suppression in pancreatic cancer. Last author DOI 10.1073/pnas.2504718122↗
  6. A radiomics-based model for predicting lymph nodes metastasis of pancreatic ductal adenocarcinoma: a multicenter study. Last author DOI 10.1186/s13244-025-02025-2↗
  7. Signal enhancement ratio of multi-phase contrast-enhanced MRI: an imaging biomarker for survival in pancreatic adenocarcinoma. Last author DOI 10.1007/s00330-024-10746-z↗
  8. Development of a radiomics-based model to predict occult liver metastases of pancreatic ductal adenocarcinoma: a multicenter study. Last author DOI 10.1097/js9.0000000000000908↗
  9. Visual Investigation of Tumor-Promoting Fibronectin Potentiated by Obesity in Pancreatic Ductal Adenocarcinoma Using an MR/NIRF Dual-Modality Dendrimer Nanopro… Last author DOI 10.1002/adhm.202300787↗
  10. Noninvasive Visualization of Obesity-Boosted Inflammation in Orthotopic Pancreatic Ductal Adenocarcinoma Using an Octapod Iron Oxide Nanoparticle. Last author DOI 10.1021/acsabm.0c00841↗
  11. Transcriptomic Analyses and Potential Therapeutic Targets of Pancreatic Cancer With Concomitant Diabetes. Last author DOI 10.3389/fonc.2020.563527↗
  12. Targeting of an antecedent proteinase by an activatable probe with deep tissue penetration facilitates early visualization and dynamic malignancy evaluation of… Last author DOI 10.1039/c9bm00441f↗
  13. Effects of VCP979 Novel p38 Mitogen Activated Protein Kinase Inhibitor on Progression of Pancreatic Cancer in Mouse Model with Diabetic Conditions. Last author DOI 10.1166/jbn.2019.2775↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ben Zhao · 7 shared papers, 2024–2026 · strength 1.40
  2. Liwen Zhu · 4 shared papers, 2024–2026 · strength 0.82
  3. Cong Xia · 3 shared papers, 2024–2025 · strength 0.53
  4. Tingting Xu · 4 shared papers, 2019–2020 · strength 0.51
  5. Jianqiong Zhang · 2 shared papers, 2025 · strength 0.43
  6. Xue Yang · 2 shared papers, 2025 · strength 0.43
  7. Xiaoyuan Shawn Chen · 2 shared papers, 2020–2025 · strength 0.35
  8. Hui Mao · 2 shared papers, 2019–2020 · strength 0.25
  9. Jiawei Du · 1 shared paper, 2025 · strength 0.22
  10. Xin Li · 1 shared paper, 2025 · strength 0.21
  11. Lu Gan · 1 shared paper, 2025 · strength 0.21
  12. Gao‐Jun Teng · 1 shared paper, 2025 · strength 0.21
  13. Shanmiao Gou · 1 shared paper, 2025 · strength 0.21
  14. Jiaqi Qin · 1 shared paper, 2025 · strength 0.21
  15. Yuling Sun · 1 shared paper, 2025 · strength 0.21
  16. Wei Wei · 1 shared paper, 2026 · strength 0.20
  17. Qi Zhang · 1 shared paper, 2026 · strength 0.20
  18. Shuai Ming · 1 shared paper, 2026 · strength 0.20
  19. Tingting Xu · 1 shared paper, 2023 · strength 0.19
  20. Xiangpan Meng · 1 shared paper, 2024 · strength 0.17
  21. Qian Yu · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.